

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

TMD8

RRID:CVCL_A442

Type: Cell Line

Proper Citation

RRID:CVCL_A442

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A442

Proper Citation: RRID:CVCL_A442

Description: Cell line TMD8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: [PMID:16780947](#), [PMID:20054396](#), [PMID:21179087](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:25485619](#), [PMID:26589293](#), [PMID:26787899](#), [PMID:27566572](#), [PMID:29416618](#), [PMID:29666304](#)

Comments: Miscellaneous: STR profile from personal communication of Gachova, Daniela., Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572)., Population: Japanese.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TMD8

Synonyms: TMD-8, Tokyo Medical and Dental university 8

Cross References: EFO:EFO_0006496, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-4956, BioGRID_ORCS_Cell_line:748, cancercellines:CVCL_A442, ChEMBL-Cells:ChEMBL4295480, ChEMBL-Targets:ChEMBL4296503, CLS:305729, Cosmic:1486587, Cosmic:1945194, Cosmic:2129635, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM1059801, GEO:GSM1374963, GEO:GSM1527304, GEO:GSM1527305, GEO:GSM1527306, GEO:GSM1527307, GEO:GSM1527308, GEO:GSM1527309, GEO:GSM1890021, GEO:GSM1890022, GEO:GSM1890023,

GEO:GSM1890024, GEO:GSM2037048, GEO:GSM2037049,
PharmacoDB:TMD8_1600_2019, Progenetix:CVCL_A442,
PubChem_Cell_line:CVCL_A442, Wikidata:Q54972694

ID: CVCL_A442

Record Creation Time: 20220427T221631+0000

Record Last Update: 20260913T010228+0000

Ratings and Alerts

No rating or validation information has been found for TMD8.

No alerts have been found for TMD8.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Wang B, et al. (2026) Axes of biological variation in diffuse large B cell lymphoma. Cancer cell.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. Blood neoplasia, 3(2), 100214.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. Cancer research.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF κ B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling :

CCS, 22(1), 415.

Phelan JD, et al. (2024) Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. *Cancer cell*, 42(2), 238.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Wu Y, et al. (2024) Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase-targeted protein degrader BGB-16673. *British journal of pharmacology*.

Li W, et al. (2024) Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. *Molecular cancer therapeutics*, 23(1), 35.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. *The Journal of experimental medicine*, 221(5).

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Delage L, et al. (2023) BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. *Blood*, 141(10), 1209.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.